Middle East and Africa Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Non Clear Cell Renal Cell Carcinoma), Product (Platform Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Industry Trends and Forecast to 2030.
Middle East and Africa Kidney Cancer Diagnostics Market Analysis and Size
Kidney cancer begins when healthy cells in one or both kidneys change and grow uncontrollably, forming a mass called a cortical tumor. The tumor can be malignant, indolent or benign. Malignancy is cancer, which means it can grow and spread to other parts of the body. An indolent tumor is also cancer, but this type of tumor rarely spreads to other parts of the body. A benign tumor means that the tumor can grow but not spread.
The rising awareness about kidney cancer Middle East and Africa has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved diagnostic procedures for kidney cancer also contributes to the rising demand for kidney cancer diagnostics testing.
The Middle East and Africa kidney cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in the field of kidney diagnosis and development is expected to further boost the market growth. However, tissue damage due to high radiation exposure from imaging tests is expected to hamper the growth of the Middle East and Africa kidney cancer diagnostics market in the forecast period.
Data Bridge Market Research analyzes that the kidney cancer diagnostics market is expected to reach a value of USD 896.76 million by 2030, at a CAGR of 4.6% during the forecast period. Imaging accounts for the largest test type segment in the market due to rising demand for smart devices, and increasing health expenditure has accelerated the demand for smart medical devices.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Non Clear Cell Renal Cell Carcinoma), Product (Platform Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).
|
|
Countries Covered
|
South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of the Middle East and Africa.
|
|
Market Players Covered
|
Siemens Healthcare GmbH, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene N.V., GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D, and CD Genomics, and BD, among others
|
Market Definition
Kidney cancer, commonly known as renal cancer, is a condition in which kidney cells develop into malignant (cancerous) tumors and expand uncontrollably. One of the top 10 most prevalent cancers is kidney cancer. Kidney cancer is fatal, and the diagnosis process also has safety issues; it is not cost-effective. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. About 40% of kidney growths are tiny, localized masses. Localized refers to a tumor that has not spread from its original location. Kidney masses cannot be detected with regular laboratory procedures. Diagnosis of kidney cancer includes biopsy procedures, blood tests, and Imaging tests. Advanced kidney cancer therapies, like immunotherapy, radiation therapy, etc., are advised. Due to cutting-edge methods, nonsurgical procedures like cryoablation (which freezes cancer cells) and radiofrequency ablation are sometimes used to treat minor kidney tumors (heat cancer cells).
Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. More than 43,000 men and 25,000 women are diagnosed with kidney and renal pelvis cancer each year, and 9,000 men and 5,000 women pass away as a result of this illness. However, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to restrain market growth.
Middle East and Africa Kidney Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Prevalence of Kidney Cancer
All ages can be affected by this type of cancer. Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Kidney cancer usually has no signs or symptoms in its early stages. Over time, signs and symptoms may occur, including blood in the urine, which may appear pink, red, or cola-colored, back or side pain that does not go away, loss of appetite, unexplained weight loss, fatigue, and fever. In adults, kidney cancer is the most common type of cancer. Young children are more likely to develop a type of kidney cancer called Wilms tumor. Renal cancer (also known as kidney cancer or renal cell adenocarcinoma) is the 14th most common cancer worldwide. It is 9th among men and 14th among women. In 2020, more than 30,000 new cases of kidney cancer were diagnosed.
Due to various risk factors such as smoking, obesity, high blood pressure (hypertension) or family history of kidney cancer, patients with kidney cancer is rising Middle East and Africa and becoming a significant socio-economic issue. Thus the rising number of patients with kidney cancer increases the demand for kidney cancer diagnostics products which act as a driver in the Middle East and Africa kidney cancer diagnostics market.
- Increase in Diagnostic Procedures for Kidney Cancer
Techniques used to diagnose kidney cancer include ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and, sometimes, positron emission tomography (PET) scans. Treatment for kidney cancer with a slow growth rate may involve monitoring. Chemotherapy for malignant is occasionally combined with radiation therapy and stem cell transplant. The increasing cancer rates have been a boosting factor for the increasing diagnostic product approval.
Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for kidney cancer diagnosis treatment. This is expected to act as a driver for the growth of the Middle East and Africa kidney cancer diagnostics market.
Opportunity
-
Rising Preference for Preventive Health Check-Ups
Preventive health check-up is preventive actions performed for the initial detection of kidney cancer disease. Also, a rising preference for preventive health check-ups provides a safeguard against likely exposure to any disease in the future.
Awareness to promote screening is the most important component of kidney cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.
Preventive kidney cancer check-up is performed with the help of various diagnostic test, which includes biopsy, immunohistochemistry, cancer screening, MRI and among others.
People are relatively more prone to kidney cancer diseases. Therefore, they require going through regular check-ups to facilitate physicians develop an understanding of diseases and to provide better treatment to a patient who is suffering from cancer, for the reason rising preference for preventive health check-ups is expected to act as a driver for the growth of Middle East and Africa kidney cancer diagnostics market.
Restraint/Challenge
- Strict Regulations And Standards For The Approval And Commercialization Of Kidney Cancer Diagnostic Products
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products Middle East and Africa that have regulations and a different body for the regulatory procedures.
Manufacturers first have to check the CE mark approval for their product's commercialization into the Middle East and Africa market. The stringent regulatory policies are expected to hinder the development of the cancer diagnostic market. The regulatory requirement for approvals of marketing or CE certification and application of laws and regulations could lead to major business changes or paying penalties, including the potential loss of business licenses. The resources and costs required to comply with these laws, rules, and regulations are high.
The regulatory requirement for marketing approvals, declaration of conformity, and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval or failing to get CE to mark approval on the products, manufacturers are not able to launch their product in the Middle East and Africa market, and for this reason, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to act as a restrain for the Middle East and Africa kidney cancer diagnostics market.
Recent Developments
- In November 2022, Koninklijke Philips N.V. announced the Middle East and Africa launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio.
- In October 2022, General Electric Company had collaborated with several research institutes like the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics.
- In July 2022, Canon Medical Systems USA Inc. announced the completion of the acquisition of NXC Imaging, a medical imaging equipment distributor and service provider located in Minnesota, U.S. This results in expanding the service outreach in the Middle East and Africa market.
Middle East and Africa Kidney Cancer Diagnostics Market Scope
The Middle East and Africa kidney cancer diagnostics market is segmented into eight notable segments based on test type, cancer stage, tumor type, product, application, technology, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Test Type
- IMAGING TEST
- BIOMARKER TEST
- BLOOD TEST
- BIOPSY
- GENETIC TEST
- OTHERS
On the basis of test type, the Middle East and Africa kidney cancer diagnostics market is segmented into imaging, biomarker test, blood test, biopsy, genetic tests, and others.
Cancer Stage
- STAGE I
- STAGE II
- STAGE III
- STAGE IV
On the basis of cancer stage, the Middle East and Africa kidney cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV.
Tumor Type
- RENAL CELL CARCINOMA
- CLEAR CELL RENAL CELL CARCINOMA
- NON-CLEAR CELL RENAL CELL CARCINOMA
On the basis of tumor type, the Middle East and Africa kidney cancer diagnostics market is segmented into renal cell carcinoma, Clear cell renal cell carcinoma, and non-clear cell renal cell carcinoma.
Product
- PLATFORM BASED PRODUCTS
- INSTRUMENT BASED PRODUCTS
- KITS AND REAGENTS
- OTHER CONSUMABLES
On the basis of product, the Middle East and Africa kidney cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables.
Technology
- FLUORESCENT IN SITU HYBRIDIZATION
- NEXT GENERATION SEQUENCING
- FLUOROIMMUNOASSAY
- COMPARATIVE GENOMIC HYBRIDIZATION
- IMMUNOHISTOCHEMICAL
- OTHERS
On the basis of technology, the Middle East and Africa kidney cancer diagnostics market is segmented into fluorescent in situ hybridization, next-generation sequencing, fluorimmunoassay, comparative genomic hybridization, immunohistochemical, and others.
Application
- SCREENING
- DIAGNOSTIC AND PREDICTIVE
- PROGNOSTIC
- RESEARCH
On the basis of application, the Middle East and Africa kidney cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research.
End User
- HOSPITALS
- CANCER RESEARCH CENTERS
- ACADEMIC INSTITUTES
- DIAGNOSTIC CENTERS
- AMBULATORY SURGICAL CENTERS
- OTHERS
On the basis of end users, the Middle East and Africa kidney cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
Distribution Channel
- DIRECT TENDERS
- RETAIL SALES
- OTHERS
On the basis of distribution channel, the Middle East and Africa kidney cancer diagnostics market is segmented into direct tender, retail sales and others.
Middle East and Africa Kidney Cancer Diagnostics Market Regional Analysis/Insights
The Middle East and Africa kidney cancer diagnostics market is analyzed and market size information is provided based on country, test type, cancer stage, tumor type, product, application, technology, end user and distribution channel.
The countries covered in this market report are South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of the Middle East and Africa.
South Africa is dominating the market due to the rise in technological advancement in the healthcare devices market.
Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and the challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Kidney Cancer Diagnostics Market Share Analysis
The kidney cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the kidney cancer diagnostics market.
Some of the major players operating in the market are Siemens Healthcare GmbH, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene N.V., GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D, and CD Genomics, and BD, among others.
SKU-